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E-mail address: lorenzomoretta@ospedale-gaslini.gNatural killer cells are important players of the innate immunity. In humans, they express HLA-class
I-speciﬁc inhibitory receptors including the allotypic-speciﬁc KIR and various activating receptors.
In most instances, in an autologous setting NK cells do not kill self cells. In contrast, in an allogeneic
setting as the haploidentical hematopoietic stem cell transplantation to cure high risk leukemias,
donor-derived NK cells may express inhibitory KIR that are not engaged by the HLA-class I alleles
(KIR ligands) expressed by recipient cells. Such ‘‘alloreactive’’ NK cells may be responsible for the
eradication of leukemia blasts escaping the preparative regimen, residual host dendritic cells and
T lymphocytes, thus preventing leukemia relapse, GvHD and graft rejection, respectively. These
NK-mediated effects result in a sharp improvement of the estimated 5 years survival.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction cytolytic activity, require activating signals generated upon effec-Natural killer (NK) cells are an important component of the in-
nate immunity. They are regulated by a number of receptors with
opposite function that ﬁnely tune potent effector functions such as
cytolytic activity and production of cytokines playing a major role
in inﬂammation and regulation of both innate and adaptive im-
mune responses [1–6].
The most relevant inhibitory NK receptors recognize major his-
tocompatibility (MHC) class I molecules and ‘‘protect’’ normal cells
from autologous NK cell-mediated killing [7–9]. On the other hand,
cells with down-regulated MHC class I molecules (as in the case of
tumor transformation or viral infection) become susceptible to NK-
mediated killing. In humans, inhibitory receptors speciﬁc for HLA
class I molecules consist of two distinct families: (1) killer Ig-like
receptors (KIRs) that belong to the immunoglobulin superfamily
and are speciﬁc for determinants shared by groups of HLA-A, -B
or -C alleles, (2) CD94/NKG2A a heterodimer related to C-type lec-
tins that recognizes HLA-E (HLA class Ib molecules) [7–10]. As
receptor-mediated inhibition of NK cell function represents a ma-
jor fail-safe mechanism to prevent killing of normal HLA-class I+
autologous cells, it is clear that NK cells, in order to exert theirchemical Societies. Published by E
e.it (L. Moretta).tor/target cell interaction. Indeed, various triggering receptors in-
volved in natural cytotoxicity have been identiﬁed and
molecularly characterized [11]. The NK cell activating receptors
primarily involved in tumor cell killing are NKp46 [12–14],
NKp30 [15] and NKp44 [16,17], collectively referred to as natural
cytotoxicity receptors (NCR). NCR surface expression is mostly re-
stricted to NK cells. In particular, NKp46 is considered a reliable
marker for NK cell identiﬁcation in humans and mice. Other acti-
vating receptors playing a relevant role in tumor cell lysis are
NKG2D [18], a type II membrane protein characterized by a lec-
tin-like domain [19] that recognizes MICA/B or ULBP proteins
[20], and DNAM-1 [21] that is speciﬁc for poliovirus receptor
(PVR, CD155) and Nectin-2 (CD112) [22]. Notably, PVR and Nec-
tin-2, two members of the nectin family, may be over-expressed
on tumor cells of different origin [22]. Recognition of ligands that
are induced upon tumor transformation or viral-infection (and, in
general, by cell stress) is likely to represent a mechanism that con-
tributes to NK cell focalization on abnormal cells.
2. KIR-mediated recognition of allotypic determinants of HLA-
class I molecules
That NK cells may sense MHC allelic differences on target cells
was ﬁrst suggested by the hybrid resistance phenomenon in whichlsevier B.V. All rights reserved.
Table 1
KIRs: structure and speciﬁcity.
KIR Domain
composition
ITIM HLA-speciﬁcity CpG ODN-
bindingb
2DL1 D1 + D2 Yes HLA-CLys80 (C2 epitope) –
2DL2 D1 + D2 Yes HLA-CAsn80 (C1 epitope)a –
2DL3 D1 + D2 Yes HLA-CAsn80 (C1 epitope)a –
2DL4 D0 + D2 Yes HLA-G ++
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grafts [23]. Subsequently, parallel studies in mice and humans al-
lowed clarifying the general mechanisms underlying this NK-med-
iated function. In humans, two surface molecules expressed by
subsets of NK cells were originally identiﬁed [24,25]. Functional
analysis (e.g., mAb-mediated masking of this molecules prior to
cytolytic assays against appropriate target cells) revealed that they
are inhibitory receptors speciﬁc for distinct groups of HLA-C alleles
[26]. Moreover, molecular cloning revealed novel members of the
Ig superfamily characterized by two extracellular Ig-like domains
and by two Immunoreceptor Tyrosine-based Inhibition Motifs
(ITIM) in the cytoplasmic portion (KIR2DL) [27,28]. In particular,
KIR2DL1 recognizes the subset of HLA-C allotypes carrying a lysine
at position 80 (referred to as C2 epitope) whereas KIR2DL2/L3 rec-
ognize the alternative HLA-C allotypes characterized by an aspara-
gine at the same position (referred to as C1 epitope). However,
KIR2DL2/L3 can also recognize the C2 epitope, although with low
afﬁnity [29]. Subsequently, two inhibitory KIRs characterized by
three Ig-like domains (KIR3DL) and displaying HLA speciﬁcity were
also cloned. In particular, KIR3DL1 recognizes HLA-B and HLA-A al-
leles sharing the Bw4 public epitope whereas KIR3DL2 recognizes
HLA-A3 and HLA-11 [28,30–32]. Activating forms of KIR (aKIRs),
characterized by a short cytoplasmic tail lacking ITIM, were also
identiﬁed and cloned (KIR2DS and KIR3DS) [33,34]. In spite of
the striking homology in the extracellular region between some
of the aKIRs and their inhibitory counterparts the speciﬁcity for
HLA-class I molecules has been unequivocally documented only
for KIR2DS1 and KIR2DS4 activating receptors [33,35–37]. Impor-
tantly, a novel KIR-associated function has recently been recog-
nized: KIR3DL2 can bind CpG-ODN and shuttle them from the
cell surface to the endosomal compartments where TLR9 is local-
ized [38,39]. This leads to NK cell activation and cytokine produc-
tion. Notably, the capability of binding CpG-ODN has been assessed
also for other KIRs characterized by a D0 domain. Table 1 summa-
rizes the structural characteristics of the known KIRs and their spe-
ciﬁc ligands.
A clonal-like expression was found to be a characteristic shared
by all KIRs [7] with the only exception of KIR2DL4. Analysis of NK
cell clones revealed that individual clones expressed different sets
of inhibitory or activating KIRs, however, under normal conditions,
most but not all, NK cells (see below) expressed at least one self-
reacting inhibitory receptor, either a KIR or CD94/NKG2A [6–10].
KIRs may also be expressed by some cytolytic T lymphocytes
[40–42]. These T cells displayed KIR repertoires similar to those
of NK cells from the same individual. Because T cells are subjected
to maturation constraints different from those of NK cells, this
could further suggest that the expressed KIR repertoire is primarily
determined by genetic rather than microenvironmental and/or
selective factors. This interpretation is further suggested by data
from bone marrow transplanted patients whose KIR repertoires
of NK cells originated from donor hematopoietic precursors were
consistently of donor type [43]. However, more recent data re-
vealed that HLA-class I may inﬂuence the NK cell function and, in
part, the degree of KIR expression (see below).2DL5 D0 + D2 Yes Not deﬁned N.D.
2DS1 D1 + D2 No HLA-CLys80 (C2 epitope) –
2DS2 D1 + D2 No Not deﬁned –
2DS3 D1 + D2 No Not deﬁned N.D.
2DS4 D1 + D2 No HLA-A11, some HLA-C alleles N.D.
2DS5 D1 + D2 No Not deﬁned –
3DL1 D0 + D1 + D2 Yes HLA-B and HLA-A (Bw4+) +++
3DL2 D0 + D1 + D2 Yes HLA-A3, -A11 +++
3DL3 D0 + D1 + D2 Yes Not deﬁned N.D.
3DS1 D0 + D1 + D2 No Not deﬁned +++
a 2DL2 and 2DL3 recognize weakly also HLA-CLys80 (C2 epitope) and few HLA-B
alleles that bear the C1 epitope (e.g., HLA-B*4601 and HLA-B*7301) [29,48].
b Binding capability of the indicated KIRs (as soluble KIR molecules) has been
detected by ELISA.3. Identiﬁcation of ‘‘alloreactive’’ NK cells
As previously mentioned, in an autologous setting, NK cells can
kill only cells that do not express sufﬁcient surface densities of
HLA-class I molecules. In contrast, in an allogeneic setting, some
NK cells may kill non-self cells. ‘‘Alloreactive’’ human NK cells were
originally discovered over two decades ago [44]. Subsequently, it
became evident that NK cells could kill allogeneic target cells when
they expressed only inhibitory KIRs recognizing self HLA-class I
allotype missing on allogeneic target cells (‘‘missing selfrecognition’’) [45]. In addition, alloreactive NK cells should not
express CD94/NKG2A since HLA-E molecules are present on all
HLA-class I+ cells [10,46]. Notably, killing of allogeneic cells also
depends on the surface density of major activating NK receptors
and/or their ligands on target cells [46,47]. More recently, KIR2DS1,
that recognizes the C2 epitope [35,36], was demonstrated to play a
substantial role in mediating alloreactivity [36,48]. Indeed, when
KIR2DS1+ NK cells are derived from C1/C2 or C1/C1 donors, activa-
tion via KIR2DS1 may overcome the KIR2DL2/3 or the CD94/
NKG2A-mediated inhibition resulting in an efﬁcient lysis of C2/
C2 leukemias [48], T cell blasts and dendritic cells [49]. Accord-
ingly, the expression of KIR2DS1 may reveal NK cells endowed
with alloreactivity and need to be taken into account to deﬁne
more accurately the size of the alloreactive NK cell subset. As dis-
cussed below, this has major implications in successful haploiden-
tical hematopoietic stem cell transplantation (HSCT).
4. NK alloreactivity in haploidentical HSCT
Allogeneic HSCT can cure leukemias through (1) a myelo-abla-
tive and immunosuppressive radio- and/or chemotherapy-based
‘‘conditioning’’ regimen and (2) alloreactivity mediated by donor
T cells present in the graft [43,50]. T cells favor the HSC engraft-
ment and can eradicate leukemia cells escaping the conditioning
regimen and potentially causing relapses [43,50]. However, only
60% of patients have HLA-matched siblings or unrelated donors.
Delays, related to donor search and/or HSC isolation and shipping,
may represent additional obstacles. On the other hand, most pa-
tients, especially of pediatric age, have a family member who is
identical for one HLA haplotype and fully mismatched for the other
(100% of parents and 50% of siblings fulﬁll this criterion) who may
promptly serve as HSC donor [51,52]. Two groups of ‘‘haploidenti-
cal’’ transplants could be identiﬁed. The ﬁrst included donor–reci-
pient pairs in which donor-derived NK cells express KIRs that
recognize HLA-class I molecules expressed by the donor but absent
in the patient (i.e., ‘‘KIR/KIR-ligand mismatch’’ in graft versus host,
GvH, direction). In these cases, NK cells of the donors are ‘‘alloreac-
tive’’ (Fig. 1). In the second category, all KIR expressed by NK cells
recognized the HLA-class I alleles of the patient (lack of KIR/KIR-
ligand mismatch). The presence of alloreactive NK cells has been
found to positively correlate with the successful outcome of
transplantation either in adults with acute myeloid leukemias
(AML) [52,54] or in pediatric patients with high risk lymphoblastic
leukemias (ALL) [48,55].
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Fig. 1. Generation of alloreactive NK cells and their therapeutic role in haploidentical hematopoietic stem cell transplantation. During the ﬁrst 2 weeks, precursors undergo
intense proliferation and become committed to the NK cell lineage. At later stages, the proliferative activity declines. NK cells ﬁrst acquire CD94/NKG2A receptors and the
capability of secreting cytokines (mainly IFN-c and TNF-a), later they express KIR and increase their cytolytic potential that is maximal in KIR+ NK cells.
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by the analysis of the KIR gene proﬁle of the donor and by the HLA
class I typing of both donor and recipient, the actual presence and
size of the alloreactive cell NK subset can be assessed by cytoﬂuo-
rimetric analysis. In particular, alloreactive NK cells are identiﬁed
as a subset expressing only inhibitory KIR speciﬁc for the mis-
matched KIR-ligand and lacking also the HLA-E-speciﬁc NKG2A.
In addition they can express activating KIR. In this context, major
progresses in the phenotypic characterization of NK cells have re-
cently been achieved thanks to the identiﬁcation of mAbs discrim-
inating between inhibitory and activating KIRs. Thus, in virtually
all instances, it is now possible to distinguish KIR3DL1 from
KIR3DS1, KIR2DL1 from KIR2DS1, and KIR2DL3 (but not KIR2DL2)
from KIR2DS2 [48,56]. Notably, the presence of activating KIRs
can be functionally assessed/conﬁrmed also by the use of redi-
rected killing assays [48]. In addition, evaluation of the cytolytic
activity of donor NK cells against leukemic blasts of the patient
(or, alternatively, against appropriate EBV-induced B cell lines)
can be performed to select the donor with the best alloreactive
capacity. Importantly, the degree of cytolytic activity generally cor-
relates with the size of phenotypically-deﬁned alloreactive NK cell
subsets [46,48].
5. Origin of donor’s alloreactive NK cells in the recipient and
persistence over time
In studies by Velardi’s group alloreactive NK cells were detected
for up to 1 year after transplantation [54]. Recent studies have con-
ﬁrmed and extended these ﬁndings. Donor alloreactive NK cell
populations have been detected both by phenotypic and functional
(cytolytic activity) criteria in several pediatric patients with high-
risk leukemias over 5 years after transplantation [48]. In these
studies, a great variability in the size of the alloreactive NK cell
population was observed in different donors and in patients
post-transplantation. Importantly, patients characterized by high
proportions of donor-derived alloreactive NK cells were
disease-free after long time intervals and a correlation was found
between size of the alloreactive NK subset and clinical outcome[48,55]. The alloreactive NK subset was detectable starting at 6–7
weeks after transplantation and, in most instances, the pattern of
expressed KIRs was similar to that originally found in the donor
[48,55]. This was somehow surprising. Indeed, during maturation,
NK cells require recognition of self-MHC-class I to acquire full
function (NK cell ‘‘licensing’’ or ‘‘education’’) [57–59]. In view of
these data, how would donor NK cell precursors give raise to allo-
reactive NK cells, i.e., effector cells capable of killing leukaemia
cells? A likely explanation is that, in haplo-HSCT, the infusion of
‘‘megadoses’’ of CD34+ cells may provide a BM microenvironment
predominantly of donor type [53,60]. Under these conditions, the
process of NK cell education would be similar to that occurring
in the donor thus allowing the generation of ‘‘licensed’’ alloreactive
NK cells. In addition, one may ask why alloreactive NK cells do not
mediate GvHD. NK cells predominantly attack the hematopoietic
cells of the host, but not tissues that are common targets of T-
cell-mediated GvHD. In the hybrid resistance phenomenon in mice,
NK cells of F1 rejected parental BM graft but did not attack other
tissues [23]. Ruggeri et al. obtained direct evidence that murine
alloreactive NK cells do not cause GvHD, while infusion of alloge-
neic T cells killed all the mice [52]. The resistance of recipient nor-
mal tissues other than the hematopoietic ones is related to the lack
or low expression of ligands for activating NK receptors [22]. These
authors also showed that alloreactive NK cells killed host DC, thus
further reducing the risk of GvHD. GvHD is initiated by donor T cell
recognizing host DC and initiating an alloreactive response leading
to proliferation and functional maturation of both CD4+ and CD8+
donor T cells. In addition, alloreactive NK cells kill residual lym-
phoid cells, thus reducing the risk of graft rejection [52,53] (see
Fig. 1).
6. Conclusions
The identiﬁcation of NK cell receptors and studies on their spec-
iﬁcity and function have provided a great opportunity for their ra-
pid exploitation in the treatment of high risk leukemias.
Notably, the discovery of NK-cell alloreactivity has represented
a true revolution in allo-HSCT, showing that also innate immunity
1566 L. Moretta et al. / FEBS Letters 585 (2011) 1563–1567may be crucial for a successful patient’s outcome. Moreover, this
discovery has important implications in the criteria for selecting
the best donor in the context of haploidentical HSCT. However,
the mechanisms of NK alloreactivity to cure leukemias require fur-
ther investigation. For example, it is important to better deﬁne the
role of activating NK receptors in host recognition, the interactions
between NK and other cell types, and the migratory capability of
alloreactive NK cells into tissues [55,61].
Overall, these studies represented a major breakthrough in the
cure of otherwise fatal leukemias including adult AML and pediat-
ric high risk ALL [48,55]. The estimated 5-year survival in children
with high risk ALL transplanted from an NK alloreactive relative is
over 70%. It is predictable that further improvements will be ob-
tained by exploiting the infusion of mature alloreactive NK cells di-
rectly isolated from the donor to prevent leukemic relapses,
particularly during the time interval necessary for alloreactive
NK cells to develop from donor HSC after transplantation [55].
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